蒙特卡洛模拟法在抗菌药物治疗ICU患者大肠埃希菌感染时初始给药方案制订中的应用
x

请在关注微信后,向客服人员索取文件

篇名: 蒙特卡洛模拟法在抗菌药物治疗ICU患者大肠埃希菌感染时初始给药方案制订中的应用
TITLE:
摘要: 目的:为抗菌药物治疗重症加强护理病房(ICU)患者大肠埃希菌(Escherichia coli,E. coli)感染时初始给药方案的制订提供参考。方法:基于CHINET中国细菌耐药监测网2016年发布的关于医院的E. coli耐药监测报告,收集全国19所三级甲等医院标示为ICU病区临床分离的E. coli,选取对E. coli耐药率低于40%且临床实际工作中使用率较高的抗菌药物为研究对象,拟定模拟给药方案,运用蒙特卡洛模拟法模拟不同给药方案对ICU病区“E. coli感染患者”中10 000“例”的临床疗效,以% fT>MIC>50%(哌拉西林他唑巴坦、头孢哌酮舒巴坦)、% fT>MIC>40%(美罗培南)、fcmax/MIC>10(阿米卡星)为目标阈值,计算“群体患者”达到目标阈值的累积响应百分率(CFR),最佳给药方案要求CFR≥90%。并与临床ICU病区275例病例进行对照。结果:确定了4种抗菌药物,分别为头孢哌酮舒巴坦、哌拉西林他唑巴坦、美罗培南和阿米卡星;共模拟了16种给药方案,其中头孢哌酮舒巴坦1种“3.0 g,q8 h”,哌拉西林他唑巴坦3种“2.25 g,q6 h”“3.375 g,q8 h”“3.375 g,q6 h”,美罗培南2种“0.5 g,q8 h”“1.0 g ,q8 h”,阿米卡星3种“0.4 g,q24 h”“0.6 g,q24 h”“0.8 g,q24 h”,其CFR均大于90%,均可作为初始给药方案。临床结果与模拟结果基本一致。结论:上述哌拉西林他唑巴坦、头孢哌酮舒巴坦、美罗培南、阿米卡星给药方案均可作为ICU患者E. coli感染时的初始经验药物选择。
ABSTRACT: OBJECTIVE: To provide reference for the formulation of primary medication regimen for antibacterial drug treatment of ICU patients with Escherichia coli infection. METHODS: Based on the surveillance report on E. coli resistance in hospitals issued by CHINET China bacterial drug resistance surveillance network in 2016, 19 third class A hospitals in China were collected as E. coli clinically isolated from ICU wards. Antibiotics with resistance rate of less than 40% to E. coli and with high utilization rate in clinical practice were selected as the research objects, and a simulated drug delivery scheme was formulated. Monte Carlo simulation method was used to simulate the clinical effect of different dosage regimens on 10 000 cases among “patients with E. coli infection” in ICU wards. The target thresholds were %fT>MIC>50% (piperacillin/tazobactam, cefoperazone/sulbactam),%fT>MIC>40% (meropenem), fcmax/MIC>10 (amikacin). The cumulative response percentage (CFR) to the target threshold requires that CFR be greater than 90% for the optimal regimen. The results were compared with those of 275 clinical ICU pationts. RESULTS: Four antibiotics were identified, namely cefoperazone/sulbactam, piperacillin/tazobactam, meropenem and amikacin; sixteen medication regimen were simulated, including 1 kind of cefoperazone/sulbactam “3.0 g, q8 h”; 3 kinds of piperacillin/tazobactam “2.25 g,  q6 h” “3.375 g, q8 h” and “3.375 g, q6 h”; 2 kinds of meropenem “0.5 g, q8 h” “1.0 g, q8 h”; 3 kinds of amikacin “0.4 g, q24 h” “0.6 g, q24 h” and “0.8 g, q24 h”. Their CFR values were higher than 90%, all of them could be regarded as primary medication regimen. The clinical results were basically consistent with the simulation results. CONCLUSIONS: Above medication regimen of piperacillin/tazobactam, cefoperazone/sulbactam, meropenem and amikacin can be used as initial empirical drug selection for patients with E. coli infection in ICU.
期刊: 2019年第30卷第17期
作者: 姚欣凯,吴洪文,刘海林,凌宙贵
AUTHORS: YAO Xinkai,WU Hongwen,LIU Hailin,LING Zhougui
关键字: 药动学;药效学;蒙特卡洛模拟;抗菌药物;大肠埃希菌;初始给药方案
KEYWORDS: Pharmacokinetics; Pharmacodynamics;Monte Carlo simulation; Antibiotics; Escherichia coli; Primary medication regimen
阅读数: 355 次
本月下载数: 4 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!